MedTrace Logo

Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization

NCT00645697 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2008-03-28

No results posted yet for this study

Summary

One complication of uveitis which is driven by an increase in VEGF is the formation of inflammatory ocular neovascularization (ION). Here, we analyze the therapeutic role of intravitreal bevacizumab in ION not responding to standard therapy (systemic and ocular corticosteroids and systemic immunosuppressants) in a multicenter retrospective study.The natural history of subfoveal choroidal new vessels histoplasmosis, multifocal choroiditis, Harada and other inflammatory chorioretinal disorders has been very guarded, but with this new approach, we hope to stop the visual loss in these relatively young patients.

Conditions

  • Neovascularization
  • Tuberculosis
  • Multifocal Serpiginous Choroiditis
  • Harada Toxoplasmosis

Sponsors & Collaborators

  • Heidelberg University

    collaborator OTHER

  • University Hospital Tuebingen

    collaborator OTHER

  • University Hospital Freiburg

    collaborator OTHER

  • Rafic Hariri University Hospital

    lead OTHER

Principal Investigators

  • Ahmad M Mansour, MD · American University of Beirut Rafic Hariri University Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • Lebanon

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00645697 on ClinicalTrials.gov